These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18627362)

  • 1. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
    Ng SC; Kamm MA
    Aliment Pharmacol Ther; 2008 Oct; 28(7):815-29. PubMed ID: 18627362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.
    Cohen RD
    Aliment Pharmacol Ther; 2006 Aug; 24(3):465-74. PubMed ID: 16886912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
    Lichtenstein GR; Kamm MA
    Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New lessons: classic treatments, expanding options in ulcerative colitis.
    Hanauer SB
    Colorectal Dis; 2006 May; 8 Suppl 1():20-4. PubMed ID: 16594960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new: innovative concepts in inflammatory bowel disease.
    Sandborn WJ
    Colorectal Dis; 2006 May; 8 Suppl 1():3-9. PubMed ID: 16594957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
    Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
    Desreumaux P; Ghosh S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks.
    Wilson J
    Gastroenterol Nurs; 2008; 31(4):286-92. PubMed ID: 18708833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ
    J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
    Olmstead J
    J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
    Lichtenstein GR; Rubin DT; Sabesin SM; Velayos FS; Vitat P
    Rev Gastroenterol Disord; 2008; 8(1):21-30; quiz 31-2. PubMed ID: 18477967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T; Probert CS; Keshav S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Active and refractory ulcerative proctitis: an update].
    Caselli M G; Pinedo M G; Zúñiga D A; Alvarez L M
    Rev Med Chil; 2010 Jan; 138(1):109-16. PubMed ID: 20361160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A; Behrens C; Bias P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.